Drug Database
OR

Ortho-ACI

✓ Approved

Orthocell Pty, Ltd. · Cell-based Therapies · Cell-based Therapies

What is Ortho-ACI?

Ortho-ACI is a cell-based therapies developed by Orthocell Pty, Ltd.. It is approved for therapeutic indications via surgical implantation.

Drug Profile

CompanyOrthocell Pty, Ltd.
Drug ClassCell-based Therapies
RouteSurgical Implantation
StatusApproved
Sources: ClinicalTrials.gov, Orthocell Pty, Ltd.

Therapeutic Indications

Ortho-ACI is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersChondropathy✓ Approved

Related Research Articles

PubMedChemistry (Weinheim an der Bergstrasse, Germany)2026-10-15

A Green Protocol for the Deprotection of ortho-Nitrobenzyl Esters and Ethers by UVA-LED Irradiation.

Poikilidou Despoina D, Mantzourani Christiana C, Kokotos George G, Kokotos Christoforos G CG

The removal of protecting groups in synthetic organic transformations under green and mild conditions is of high interest. In this study, a green photochemical protocol for the deprotection of ortho-nitrobenzyl esters and ethers is introduced, utilizing LED 370 nm irradiation and methanol as the solvent in a short reaction time. This method was demonstrated in a number of substrates and applied in the synthesis of a cytosolic phospholipase A2 inhibitor. Direct infusion-high resolution mass spectrometry contributed to the study of the photo-release mechanism.

PMID 42876408
Read full article →
PubMedFrontiers in pharmacology2026-10-15

Mapping the antileishmanial structure-activity relationship of eugenol.

Daut Lucas L, Taylor Jonathan J, Carter Nicola S NS, Stamper Brendan D BD

Leishmaniasis is a neglected tropical disease with a devastating global impact. The current medications on the market for treating this protozoan parasitic infection are insufficient to fit the global need, with long durations of therapy, growing resistance rates, and severe adverse effects. This investigation aims to characterize an antileishmanial structure-activity relationship for the natural product eugenol. With Leishmania donovani as a model, a series of dose-response curves were performed against eugenol and several of its structural analogs. The same set of compounds was tested against the human monocyte cell THP-1 to characterize their selective toxicity. Subsequently, the pharmacokinetic parameters of the tested compounds were estimated using the in silico modelling software, Percepta®. Eugenol and its analogs demonstrated varying levels of antileishmanial potency, with 4-allylphenol (chavicol) as the most potent compound tested and with the most promising selectivity index. In comparing the potencies and structures of the compounds tested, the data suggests that the para-substituted allyl tail and the phenolic group are important to conferring potency, while the ortho-methoxy substitutions decreased potency. Furthermore, the pharmacokinetic properties of these compounds were predicted to closely resemble eugenol with little risk of cytochrome P450 (CYP) interactions. While more testing is needed to confirm the mechanisms and safety of these compounds, these results suggest eugenol analogs show promise as future antileishmanial therapies.

PMID 42876893
Read full article →
PubMedDiabetes research and clinical practice2026-10-14

Capturing human-machine interplay in automated insulin delivery systems through day-to-day variability of the automated correction index (ACI-V%).

Tumminia Andrea A, Papa Giuseppe G, Cannarella Rossella R, Galeano Francesco F et al.

The Automated Correction Index (ACI) reflects the proportion of algorithm-driven correction boluses relative to total bolus insulin in advanced hybrid closed-loop (AHCL) systems. While mean ACI has been associated with glycemic outcomes in patients with type 1 diabetes mellitus (T1DM), the clinical significance of its day-to-day variability (ACI-V%) remains unknown. In this multicenter real-world study, 330 pediatric and adult patients with T1DM using the MiniMed™ 780G system were studied. ACI-V% was defined as the coefficient of variation of daily ACI values over a 30-day period. Associations between ACI-V% and continuous glucose monitoring (CGM) metrics were assessed. Higher ACI-V% was associated with greater time in range (TIR70-180 mg/dL) and lower time above range, while no significant association with time below range was observed. ACI-V% showed an inverse correlation with mean ACI, suggesting greater day-to-day variability in settings of lower overall automated correction insulin delivery. Moreover, ACI-V% independently predicted achievement of TIR70-180 mg/dL > 70%, with a threshold of ≥ 32.6% identifying patients more likely to reach this target (sensitivity 52.4%, specificity 71.4%). ACI-V% provides an exploratory descriptor of day-to-day variability in automated correction insulin delivery that may complement mean ACI for clinical interpretation of AHCL system behavior.

PMID 42874782
Read full article →
PubMedThe Journal of organic chemistry2026-10-14

Pd(II)-Catalyzed Decarboxylative ortho-Amidation of Benzyl Thiocyanates with Oxamic Acids Unveiling -SCN as a Bidentate Directing Group.

Singh Sandeep S, Rai Prachi P, Giri Santanab S, Mishra Rakesh K RK et al.

A Pd(II)-catalyzed highly regiospecific ortho-amidation of benzyl thiocyanates with N,N-disubstituted oxamic acids has been developed using AgOAc as an oxidant. Thiocyanate (-SCN) has been introduced as a multicoordinating weak-directing group in C-H activation. The decarboxylative coupling proceeds under operationally simple conditions with a broad substrate scope and excellent functional group tolerance. A variety of substituted, secondary, and heterocyclic benzyl thiocyanates efficiently undergo ortho-amidation with diverse oxamic acids to afford a series of ortho-amidation products in moderate to excellent yields. Density functional theory (DFT) calculations established that the thiocyanate (-SCN) moiety acts as a bidentate directing group, coordinating to palladium through both nitrogen and sulfur atoms sequentially, thereby leading to the formation of an unusual monomeric Pd(III)-intermediate. This Pd(III)-intermediate preferentially undergoes reductive elimination to generate a Pd(I)-species rather than participating in single-electron oxidation or disproportionation pathways. The Pd(II)-catalyst is regenerated from Pd(I) using silver(I) as an oxidant. The established protocol offers an efficient and atom-economical route for C-H amidation, expanding the versatility of Pd-catalyzed C-H functionalization strategies.

PMID 42870511
Read full article →
PubMedThe Journal of organic chemistry2026-10-14

Dissecting Binary and Ternary Iminoboronate Assemblies: A Calorimetric Study of Thermodynamics, Kinetics, and Allosteric Effects.

Ruiz Joseba J, Laga Eduardo E, Velázquez-Campoy Adrián A, Barrio Jesús Del JD

Dynamic covalent assemblies derived from ortho-boronoaldehydes, including iminoboronates and boronate esters, are key structural motifs in adaptive materials, chemical sensors, and reversible bioconjugation strategies. Herein, we report a label-free assay based on isothermal titration calorimetry that provides access to observed thermodynamic and model-derived kinetic parameters associated with assembly formation under defined experimental conditions. The assay further reveals cooperative binding between amine-based nucleophiles and diols toward ortho-boronoaldehyde derivatives, providing new insight into multicomponent dynamic covalent systems.

PMID 42872566
Read full article →
PubMedThe Journal of organic chemistry2026-10-13

Solvent Control of Cheletropic Recombination in Benzosultine-Derived ortho-Quinodimethane Diels-Alder Reactions.

Connor Kieran P E KPE, Pei Zhipeng Z, Kroeger Asja A AA, Magann Nicholas L NL et al.

Thermolysis of benzosultines generates ortho-quinodimethanes (o-QDMs) widely used in Diels-Alder (DA) chemistry, yet productive cycloaddition is often limited by rapid cheletropic SO2 recombination to form benzosulfolenes. Combined computational and experimental studies support a model in which benzosultine thermolysis proceeds through kinetically competent o-QDM/SO2 encounter complexes positioned at the boundary between pericyclic and open-shell reactivity. Although reversible C-S homolysis accounts for efficient TEMPO trapping, stereochemical probe experiments establish that productive cycloaddition proceeds through a concerted DA pathway. The absence of o-QDM dimerization indicates that free o-QDM does not accumulate under the reaction conditions, leading to an apparent mechanistic paradox: how can intermolecular cycloaddition compete with rapid cheletropic SO2 recombination? The combined computational and experimental data are most consistent with a model in which DA reactions occur within the same solvent cage as competing SO2 recombination. As a result, cheletropic SO2 recombination is highly medium sensitive: replacing aromatic solvents such as toluene with nonpolar aliphatic hydrocarbons markedly suppresses benzosulfolene formation and reverses product selectivity in favor of productive DA cycloaddition. These findings establish solvent-controlled encounter-complex partitioning as a general strategy for improving benzosultine-derived o-QDM cycloadditions.

PMID 42864714
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Ortho-ACI